Deloitte
Haskins & Sells LLP

Chartered Accountants
One International Center,
Tower 3, 31st Floor,
Senapati Bapat Marg
Elphinstone Road (West)
Mumbai - 400 013
Maharashtra, India

Tel: +91 22 6185 6000
Fax: +91 22 6185 4101

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF Sahajanand Medical Technologies Limited

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **Sahajanand Medical Technologies Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter and six months ended September 30, 2026 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities listed in Annexure A.

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the interim financial results of 6 subsidiaries included in the consolidated unaudited financial results, whose interim financial results reflect total assets of Rs. 21,098.46 lakhs as at September 30, 2026 and total revenues of Rs. 8,564.62 lakhs and Rs. 14,838.02 lakhs for the quarter and six months ended September 30, 2026, total net profit/(loss) after tax of Rs. 683.32 lakhs and Rs. (346.24) lakhs for the quarter and six months ended September 30, 2026 and total comprehensive income/ (loss) of Rs. 683.32 lakhs and Rs. (346.24) lakhs for the quarter and six months ended September 30, 2026 respectively and net cash inflow of Rs. 28.35 lakhs for the six months ended September 30, 2026, as considered in the Statement. These interim financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the

DELOITTE HASKINS & SELLS LLP MUMBAI

Deloitte
Haskins & Sells LLP

Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of these matters.

For Deloitte Haskins & Sells LLP
Chartered Accountants
Firm Registration No. 117366W/W-100018



Terence Lewis
Partner
Membership No. 107502

UDIN: 26107502TZKEK01743



Place: Mumbai
Date: November 05, 2026

Deloitte
Haskins & Sells LLP

Annexure A:

Sr. No.	Name of the Entities:
	Parent
1	Sahajanand Medical Technologies Limited
	Subsidiaries
2	SMT Cardiovascular Private Limited
3	Sahajanand Medical Technologies Ireland Limited
4	Vascular Innovation Company Limited
5	SMT Germany Gmbh
6	Sahajanand Medical Technologies Iberia SL
7	SMT Importadora E Distribuidora De Produtos Hospitalares Ltda.
8	SMT Switzerland AG
9	SMT Polonia sp. Z o.o.
10	SMT CIS LLC
11	SMT France SAS
12	SMT USA Ltd
13	SMT Australia PTY Ltd (w.e.f. April 01, 2026)



Sahajanand Medical Technologies Limited

Registered Office: Sahajanand Estate, Wakhariawadi, Near Dabholi, Ved Road, Surat – 395 004, Gujarat, India
CIN: U33119GJ2001PLC040121, Email: investors.grievance@smt.in, Website: www.smtpl.com

Unaudited Consolidated Statement of Profit and Loss for the quarter and six month ended 30 September, 2026

(Rs. in lacs)

	Particulars	Quarter ended			Six month ended		Year ended
		30 September, 2026	30 June, 2026	30 September, 2025	30 September, 2026	30 September, 2025	31 March, 2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	**Income :**						
	Revenue from operations	37,341.01	35,166.85	29,947.09	72,507.86	58,037.22	1,21,050.42
	Other income	223.58	266.50	234.33	490.08	550.28	822.14
	Total Income (I)	**37,564.59**	**35,433.35**	**30,181.42**	**72,997.94**	**58,587.50**	**1,21,872.56**
II	**Expenses:**						
	Cost of materials consumed	7,995.42	6,307.96	7,311.96	14,303.38	12,244.25	25,823.28
	Purchase of Stock-in-trade	3,368.22	3,253.57	267.95	6,621.79	2,086.89	4,575.28
	Changes in inventories of finished goods, stock-in-trade and work-in-progress	(1,802.48)	(452.69)	(504.54)	(2,255.17)	(374.22)	(1,000.67)
	Employee benefits expense	10,127.47	9,739.10	8,628.86	19,866.57	17,212.53	35,179.13
	Finance costs	681.18	654.65	600.87	1,335.83	1,178.62	2,442.76
	Depreciation and amortisation expense	2,090.91	2,041.27	1,722.03	4,132.18	3,339.45	7,415.45
	Other expenses	11,097.00	11,460.97	9,445.52	22,557.97	18,907.54	39,407.98
	Total expenses (II)	**33,557.72**	**33,004.83**	**27,472.65**	**66,562.55**	**54,595.06**	**1,13,843.21**
III	**Profit before tax (I-II)**	**4,006.87**	**2,428.52**	**2,708.77**	**6,435.39**	**3,992.44**	**8,029.35**
IV	**Tax expense:**						
	Current tax	1,288.64	1,095.55	1,075.15	2,384.19	1,539.63	3,150.54
	Deferred tax (credit)	71.31	(176.26)	(457.15)	(104.95)	(540.89)	(1,158.41)
	Tax related to earlier periods/year	-	-	-	-	(871.14)	(871.14)
	Total tax expense (IV)	**1,359.95**	**919.29**	**618.00**	**2,279.24**	**127.60**	**1,120.99**
V	**Profit after tax (III-IV)**	**2,646.92**	**1,509.23**	**2,090.77**	**4,156.15**	**3,864.84**	**6,908.36**
VI	**Other comprehensive income**						
	Items that will not be reclassified subsequently to profit or loss						
	Re-measurement Gain/(Loss) on defined benefit obligation	-	(216.92)	288.89	(216.92)	288.89	549.05
	Income tax on above	-	50.87	(77.93)	50.87	(77.93)	(137.62)
	Items that will be reclassified subsequently to profit or loss						
	Exchange gain on translation of financial statements of foreign operations	171.08	(180.96)	1,874.39	(9.88)	3,976.92	6,237.64
	Total Other comprehensive Income (VI)	**171.08**	**(347.01)**	**2,085.35**	**(175.93)**	**4,187.88**	**6,649.07**
VII	**Total Comprehensive Income (V+VI)**	**2,818.00**	**1,162.22**	**4,176.12**	**3,980.22**	**8,052.72**	**13,557.43**
VIII	**Profit attributable to:**						
	Non-controlling interest	67.86	52.04	139.08	119.90	280.60	379.70
	Owners of the Company	2,579.06	1,457.19	1,951.69	4,036.25	3,584.24	6,528.66
IX	**Other comprehensive income for the period attributable to:**						
	Non-controlling interest	4.56	(5.22)	182.16	(0.66)	322.74	345.94
	Owners of the Company	166.52	(341.79)	1,903.19	(175.27)	3,865.14	6,303.13
X	**Total comprehensive income for the period attributable to:**						
	Non-controlling interest	72.42	46.82	321.24	119.24	603.34	725.64
	Owners of the Company	2,745.58	1,115.40	3,854.88	3,860.98	7,449.38	12,831.79
XI	**Paid-up equity share capital (Face value of Rs. 1 per share)**	981.31	981.31	976.31	981.31	976.31	981.31
XII	**Other Equity**						68,564.91
XIII	**Earnings per share (not annualised for quarter and six month ended):**						
	(Face Value Re. 1 per share)						
	Basic (Rs.)	2.63	1.48	2.00	4.11	3.67	6.67
	Diluted (Rs.)	2.56	1.45	1.94	4.01	3.56	6.48

See accompanying notes forming part of the consolidated financial results

DELOITTE HASKINS & SELLS LLP MUMBAI

Sahajanand Medical Technologies Limited MUMBAI

Explanatory Notes to the Unaudited Consolidated Financial Results:

1. The Unaudited Consolidated Financial Results for the quarter and six month ended 30 September, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 05 November, 2026 and a limited review of the same has been carried out by the Statutory Auditors of the Company.

2. The Parent Company's equity shares have been listed on Bombay Stock Exchange Limited ("BSE") and on National Stock Exchange of India Limited ("NSE") on 23 October 2026 by completing Initial Public Offering of 1,38,22,116 equity shares of face value of Re. 1 each and issue price of Rs. 344 per equity share, consisting of an offer for sale by selling shareholders. Accordingly, the above Statement of Unaudited Consolidated Financial Results for the quarter and six months ended 30 September 2026 ("the Statement") are drawn up in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, ("Listing Requirements") as amended.

3. The Unaudited Consolidated Financial Results of Sahajanand Medical Technologies Limited ("the Parent"/ "Company") and its Subsidiaries (the parent and its subsidiaries together referred to as "the Group") comprises the Consolidated Statement of Profit and Loss (including Other Comprehensive Income) for the quarter and six month ended 30 September, 2026 and Explanatory Notes (together referred to as the "Unaudited Consolidated Financial Results").

The Unaudited Consolidated Financial Results have been prepared in accordance with the recognition and measurement principle of Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013 (the "Act"), read with relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

4. The Group is engaged in the business of manufacturing Balloon Catheter, Cardiac Stents, TAVI and Occluder and the Company's Chief Operating Decision Maker (CODM) evaluates the Company's performance, allocates resources as a single segment "Cardiovascular Devices". Accordingly, no separate disclosure of segment has been made.

5. The Unaudited Consolidated Financial Results and notes are also available on the websites of Stock Exchange via www.bseindia.com and www.nseindia.com and also on the website of the Parent Company at www.smtpl.com.

For and on behalf of the Board of Directors
Sahajanand Medical Technologies Limited

Bhargav Kotadia
Managing Director and Chief Executive Officer

DIN : 06575042
Place : Mumbai
Date : 05 November 2026

Amit Kumar Khandelia
Chief Financial Officer

Place : Mumbai
Date : 05 November 2026

DELOITTE HASKINS & SELLS LLP ★ MUMBAI ★

Sahajanand Medical Technologies Limited ★ MUMBAI

Sahajanand Medical Technologies Limited

Registered Office: Sahajanand Estate, Wakhariawadi, Near Dabholi, Ved Road, Surat – 395 004, Gujarat, India
CIN: U33119GJ2001PLC040121, Email: investors.grievance@smt.in, Website: www.smtpl.com

Unaudited Consolidated Statement of Assets and Liabilities as at 30 September, 2026

(Rs. in lacs)

Particulars	As at 30 September, 2026	As at 31 March, 2026
	Unaudited	Audited
ASSETS		
1 Non-Current Assets		
(a) Property, Plant and Equipment	24,753.05	23,902.29
(b) Right of Use Assets	2,998.25	3,644.79
(c) Capital Work-in-Progress	1,458.88	751.91
(d) Goodwill	4,937.07	4,950.38
(e) Other Intangible Assets	1,144.27	1,842.01
(f) Intangible assets under development	75.98	149.25
(g) Financial Assets		
(i) Investments	2,998.44	2,245.06
(ii) Loans	369.30	382.08
(iii) Other Financial Assets	1,383.78	1,509.10
(h) Income Tax Assets (net)	98.84	80.84
(i) Deferred Tax Assets (net)	5,182.38	5,005.34
(j) Other Non-Current assets	1,647.64	2,301.41
Total Non-Current Assets	**47,047.88**	**46,764.46**
2 Current Assets		
(a) Inventories	33,026.96	30,908.79
(b) Financial Assets		
(i) Investments	3,301.28	3,610.33
(ii) Trade Receivables	31,814.80	28,625.46
(iii) Cash and Cash Equivalents	7,816.40	7,409.30
(iv) Other Bank Balances	316.32	139.08
(v) Loans	82.77	66.14
(vi) Other Financial Assets	2,251.89	2,580.75
(c) Other Current Assets	6,948.75	7,538.25
Total Current Assets	**85,559.17**	**80,878.10**
Total Assets	**1,32,607.05**	**1,27,642.56**
EQUITY AND LIABILITIES		
1 Equity		
(a) Equity share capital	981.31	981.31
(b) Other equity	72,747.20	68,564.91
Equity attributable to owners of the Company	**73,728.51**	**69,546.22**
(c) Non-controlling interest	802.47	683.23
Total Equity	**74,530.98**	**70,229.45**
Liabilities		
2 Non-Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	6,580.93	4,948.16
(ii) Lease Liabilities	1,803.13	2,249.73
(iii) Other Financial Liabilities	1,638.75	1,006.97
(b) Provisions	119.24	99.26
(c) Deferred Tax Liabilities (net)	249.88	230.64
Total Non-Current Liabilities	**10,391.93**	**8,534.76**
3 Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	23,588.98	22,004.33
(ii) Lease Liabilities	1,203.98	1,398.68
(iii) Trade Payables		
total outstanding dues of micro and small enterprises	669.90	1,311.18
total outstanding dues of creditors other than micro and small enterprises	9,624.66	9,740.08
(iv) Other Financial Liabilities	5,591.59	8,408.35
(b) Other Current Liabilities	2,136.40	1,587.40
(c) Provisions	206.40	170.00
(d) Current Tax Liabilities (net)	4,662.23	4,258.33
Total Current Liabilities	**47,684.14**	**48,878.35**
Total Liabilities	**58,076.07**	**57,413.11**
Total Equity and Liabilities	**1,32,607.05**	**1,27,642.56**

DELOITTE HASKINS & SELLS LLP MUMBAI

Sahajanand Medical Technologies Limited MUMBAI

Sahajanand Medical Technologies Limited

Registered Office: Sahajanand Estate, Wakhariawadi, Near Dabholi, Ved Road, Surat – 395 004, Gujarat, India
CIN: U33119GJ2001PLC040121, Email: investors.grievance@smt.in, Website: www.smtpl.com

Unaudited Consolidated Statement of Cash flows for the six month ended 30 September, 2026

(Rs. In Lacs)

Particulars	For the six month period ended 30 September, 2026 Unaudited	For the six month period ended 30 September, 2025 Unaudited
A Cash flows from Operating Activities		
Profit before tax	**6,435.39**	**3,992.44**
Adjustment for:		
Depreciation and amortisation expense	4,132.18	3,339.45
Finance costs	1,335.83	1,178.62
Interest income	(169.60)	(176.78)
Share based payment expenses	321.29	277.27
Unrealised exchange (gain)/loss	(1,442.77)	282.81
Profit on sale of property, plant and equipment (net)	(13.55)	(29.61)
Gain on termination of Lease	(6.83)	(25.63)
Impairment of Financial Assets (net)	(197.13)	184.12
Provision no longer required written back	-	(8.35)
Operating cash flows before movement in working capital	**10,394.81**	**9,014.34**
Movements in working capital		
Adjustment for (increase) / decrease in operating assets:		
Inventories (net of provision)	(2,104.24)	326.55
Trade Receivables and other assets	(2,481.04)	(2,759.00)
Adjustment for (decrease) in operating liabilities:		
Trade Payables and other liabilities	927.17	(3,294.96)
Cash generated from operating activities	**6,736.70**	**3,286.93**
Net income tax paid	(2,007.30)	(842.34)
Net cash generated from operating activities (A)	**4,729.40**	**2,444.59**
B Cash flows from investing activities		
Payment for purchase of Property, Plant & Equipment, Capital Work-in-Progress, intangibles, and intangible under development	(4,213.28)	(5,670.28)
Proceeds from sale of property, plant and equipment and Capital Work-in-Progress	62.81	762.83
Purchases of equity instruments designated at FVTOCI	(759.67)	(708.89)
Loans given to third party/employees (net)	(4.23)	(80.37)
Bank deposits withdrawn/ (placed) (net)	316.90	50.87
(Investment)/Redemption in debt securities (net)	316.30	(204.44)
Interest received	299.93	151.50
Net cash used in investing activities (B)	**(3,981.24)**	**(5,698.78)**
C Cash flows from financing activities		
Proceeds from long-term borrowings	1,756.28	238.11
Repayment of long-term borrowings	(125.06)	(1,111.74)
Proceeds from short-term borrowings (net)	1,643.13	3,799.67
Payment of lease liabilities (principal)	(663.57)	(627.75)
Payment of lease liabilities (interest)	(95.63)	(120.66)
Acquisition of non-controlling interest in a subsidiary*	(1,708.12)	(1,597.97)
Finance costs paid	(1,144.24)	(1,009.97)
Net cash used in financing activities (C)	**(337.21)**	**(430.31)**
Net decrease in cash and cash equivalents (A+B+C)	**410.95**	**(3,684.50)**
Cash and cash equivalents at the beginning of the period	7,409.30	10,052.02
Less: Unrealised exchange gain/ (loss) on cash and cash equivalent	(3.85)	686.27
Cash and cash equivalents at the end of the period	**7,816.40**	**7,053.79**
Reconciliation of cash and cash equivalents		
Closing balance of cash and cash equivalent	7,816.40	7,053.79
Cash and cash equivalents at the end of the period	**7,816.40**	**7,053.79**
*Payment made on deferred basis for acquisition of NCI in previous period		

Sahajanand Medical Technologies Limited MUMBAI

DELOITTE HASKINS & SELLS LLP MUMBAI

Deloitte
Haskins & Sells LLP

Chartered Accountants
One International Center,
Tower 3, 31st Floor,
Senapati Bapat Marg
Elphinstone Road (West)
Mumbai - 400 013
Maharashtra, India

Tel: +91 22 6185 6000
Fax: +91 22 6185 4101

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF Sahajanand Medical Technologies Limited

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **Sahajanand Medical Technologies Limited** ("the Company"), for the quarter and six months ended September 30, 2026 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **Deloitte Haskins & Sells LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)

DELOITTE HASKINS & SELLS LLP ★ MUMBAI ★

Terence Lewis
(Partner)
(Membership No. 107502)

UDIN: 26107502PXVFHH8012

Place: Mumbai
Date: November 05, 2026

Sahajanand Medical Technologies Limited

Registered Office: Sahajanand Estate, Wakhariawadi, Near Dabholi, Ved Road, Surat – 395 004, Gujarat, India
CIN: U33119GJ2001PLC040121, Email: investors.grievance@smt.in, Website: www.smtpl.com

Unaudited Standalone Statement of Profit and Loss for the quarter and six month ended 30 September, 2026

(Rs. In Lacs)

Particulars	Quarter ended			Six month ended		Year ended
	30 September, 2026	30 June, 2026	30 September, 2025	30 September, 2026	30 September, 2025	31 March, 2026
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I Income :						
Revenue from operations	15,858.23	15,339.14	13,496.20	31,197.37	25,844.78	55,119.60
Other income	194.71	140.24	172.72	334.95	342.68	605.83
Total Income (I)	**16,052.94**	**15,479.38**	**13,668.92**	**31,532.32**	**26,187.46**	**55,725.43**
II Expenses:						
Cost of materials consumed	5,538.87	3,870.36	4,961.90	9,409.23	8,196.72	16,181.97
Purchase of Stock-in-trade	588.55	1,518.66	662.99	2,107.21	1,487.37	4,360.92
Changes in inventories of finished goods, stock-in-trade and work-in-progress	(136.63)	492.25	(895.71)	355.62	(82.73)	(441.19)
Employee benefits expense	4,196.80	4,350.52	3,494.90	8,547.32	7,305.84	15,077.55
Finance costs	423.17	415.78	467.23	838.95	846.63	1,674.35
Depreciation and amortisation expense	507.13	474.22	507.57	981.35	969.10	2,119.26
Other expenses	3,629.93	3,055.93	2,931.76	6,685.86	5,780.45	12,147.91
Total expenses (II)	**14,747.82**	**14,177.72**	**12,130.64**	**28,925.54**	**24,503.38**	**51,120.77**
III Profit/ (Loss) before tax (I-II)	**1,305.12**	**1,301.66**	**1,538.28**	**2,606.78**	**1,684.08**	**4,604.66**
IV Tax expense:						
Current tax	340.70	419.25	473.57	759.95	533.33	874.78
Deferred tax	(18.63)	(49.68)	(155.93)	(68.31)	(159.89)	250.80
Tax related to earlier periods/year	-	-	-	-	(871.14)	(871.14)
Total tax expense (IV)	**322.07**	**369.57**	**317.64**	**691.64**	**(497.70)**	**254.44**
V Profit/ (Loss) after tax (III-IV)	**983.05**	**932.09**	**1,220.64**	**1,915.14**	**2,181.78**	**4,350.22**
VI Other comprehensive income						
Items that will not be reclassified subsequently to profit or loss						
Re-measurement Gain/(Loss) on defined benefit obligation	-	(202.12)	315.04	(202.12)	315.04	574.53
Income tax on above	-	50.87	(79.29)	50.87	(79.29)	(144.60)
Total Other comprehensive Income (VI)	**-**	**(151.25)**	**235.75**	**(151.25)**	**235.75**	**429.93**
VII Total Comprehensive Income (V+VI)	**983.05**	**780.84**	**1,456.39**	**1,763.89**	**2,417.53**	**4,780.15**
VIII Paid-up equity share capital (face Value of Rs. 10 Per share)	981.31	981.31	976.31	981.31	976.31	981.31
IX Other equity						66,752.71
X Earnings per share: (not annualised for Quarter and six month ended)						
(Face Value Re. 1 per share)						
Basic (Rs.)	1.00	0.95	1.26	1.95	2.24	4.45
Diluted (Rs.)	0.98	0.93	1.22	1.90	2.17	4.32

See accompanying notes forming part of the standalone financial results

DELOITTE HASKINS & SELLS LLP MUMBAI

Sahajanand Medical Technologies Limited MUMBAI

Explanatory Notes to the Interim Standalone Financial Results:

1. The Unaudited Standalone Financial Results for the quarter and six months ended 30 September, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 05 November, 2026 and a limited review of the same has been carried out by the Statutory Auditors of the Company.

2. The Company's equity shares have been listed on Bombay Stock Exchange Limited ("BSE") and on National Stock Exchange of India Limited ("NSE") on 23 October 2026 by completing Initial Public Offering of 1,38,22,116 equity shares of face value of Re. 1 each at an issue price of Rs. 344 per equity share, consisting of an offer for sale by selling shareholders. Accordingly, the above Statement of Unaudited Standalone Financial Results for the quarter and six months ended 30 September 2026 ("the Statement") are drawn up in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, ("Listing Requirements") as amended.

3. The Unaudited Standalone Financial Results of Sahajanand Medical Technologies Limited (the "Company") comprises the Standalone Statement of Profit and Loss (including Other Comprehensive Income) for the quarter and six month ended ended 30 September, 2026 and Explanatory Notes (together referred to as the "Unaudited Standalone Financial Results").

The Unaudited Standalone Financial Results have been prepared in accordance with the recognition and measurement principle of Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013 (the "Act"), read with relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

4. The Company is engaged in the business of manufacturing Balloon Catheter, Cardiac Stents, TAVI and Occluder and the Company's Chief Operating Decision Maker (CODM) evaluates the Company's performance, allocates resources as a single segment "Cardiovascular Devices". Accordingly, no separate disclosure of segment has been made.

5. The Unaudited Standalone Financial Results and notes are also available on the websites of Stock Exchange via www.bseindia.com and www.nseindia.com and also on the website of the Company at www.smtpl.com.

For and on behalf of the Board of Directors
Sahajanand Medical Technologies Limited

Bhargav Kotadia
Managing Director and Chief Executive Officer
DIN : 06575042
Place : Mumbai
Date: 05 November 2026

Amit Kumar Khandelia
Chief Financial Officer

Place : Mumbai
Date: 05 November 2026

DELOITTE HASKINS & SELLS LLP MUMBAI

Sahajanand Medical Technologies Limited MUMBAI

Sahajanand Medical Technologies Limited

Registered Office: Sahajanand Estate, Wakhariawadi, Near Dabholi, Ved Road, Surat – 395 004, Gujarat, India
CIN: U33119GJ2001PLC040121, Email: investors.grievance@smt.in, Website: www.smtpl.com

Unaudited Standalone Statement of Assets and Liabilities as at 30 September, 2026

(Rs. In Lacs)

	Particulars	As at 30 September, 2026	As at 31 March, 2026
		Unaudited	Audited
	ASSETS		
1	**Non-Current Assets**		
	(a) Property, Plant and Equipments	5,088.34	4,857.85
	(b) Right of Use Assets	899.18	1,220.25
	(c) Capital Work-in-Progress	626.98	157.17
	(d) Goodwill	2,963.54	2,963.54
	(e) Other Intangible Assets	224.29	152.41
	(f) Intangible assets under development	75.98	149.25
	(g) Financial Assets		
	(i) Investments	50,246.12	50,153.39
	(ii) Loans	5,371.54	5,373.99
	(iii) Other Financial Assets	881.34	921.49
	(h) Deferred Tax Assets (net)	2,431.81	2,312.63
	(i) Other Non-Current assets	1,320.96	1,369.03
	Total Non-Current Assets	**70,130.08**	**69,631.00**
2	**Current Assets**		
	(a) Inventories	14,066.84	15,063.88
	(b) Financial Assets		
	(i) Trade Receivables	12,478.83	11,651.61
	(ii) Cash and Cash Equivalents	428.26	642.33
	(iii) Other Bank Balances	4.12	4.99
	(iv) Loans	79.31	61.03
	(v) Other Financial Assets	5,050.51	8,827.39
	(c) Other Current Assets	2,890.81	3,121.92
	Total Current Assets	**34,998.68**	**39,373.15**
	Total Assets	**1,05,128.76**	**1,09,004.15**
	EQUITY AND LIABILITIES		
1	**Equity**		
	(a) Equity share capital	981.31	981.31
	(b) Other equity	68,837.89	66,752.71
	Total Equity	**69,819.20**	**67,734.02**
	Liabilities		
2	**Non-Current Liabilities**		
	Financial Liabilities		
	(i) Borrowings	3,369.18	2,595.38
	(ii) Lease Liabilities	310.61	445.01
	(iii) Other Financial Liabilities	643.37	259.87
	Total Non-Current Liabilities	**4,323.16**	**3,300.26**
3	**Current Liabilities**		
	(a) Financial Liabilities		
	(i) Borrowings	17,188.80	17,455.97
	(ii) Lease Liabilities	453.72	633.14
	(iii) Trade Payables		
	total outstanding dues of micro and small enterprises	609.44	1,238.57
	total outstanding dues of creditors other than micro and small enterprises	4,162.89	5,986.85
	(iv) Other Financial Liabilities	4,057.92	8,522.45
	(b) Other Current Liabilities	474.42	408.77
	(c) Provisions	204.18	168.83
	(d) Current Tax Liabilities (net)	3,835.03	3,555.29
	Total Current Liabilities	**30,986.40**	**37,969.87**
	Total Liabilities	**35,309.56**	**41,270.13**
	Total Equity and Liabilities	**1,05,128.76**	**1,09,004.15**

DELOITTE HASKINS & SELLS LLP ★ MUMBAI ★

Sahajanand Medical Technologies Limited ★ MUMBAI

Sahajanand Medical Technologies Limited

Registered Office: Sahajanand Estate, Wakhariawadi, Near Dabholi, Ved Road, Surat – 395 004, Gujarat, India
CIN: U33119GJ2001PLC040121, Email: investors.grievance@smt.in, Website: www.smtpl.com

Unaudited Standalone Statement of Cash flows for the six month period ended 30 September, 2026

(Rs. In Lacs)

	Particulars	For the six month period ended 30 September, 2026	For the six month period ended 30 September, 2025
		Unaudited	Unaudited
A	**Cash flows from Operating Activities**		
	Profit/(loss) before tax	**2,606.78**	**1,684.08**
	Adjustment for:		
	Depreciation and amortisation expense	981.35	969.10
	Finance costs	838.95	846.63
	Interest income	(199.72)	(74.32)
	Share based payment expenses	228.56	72.71
	Unrealised exchange loss	(519.57)	183.07
	(Profit)/Loss on sale of property, plant and equipment (net)	-	(111.04)
	Gain on termination of lease	(2.93)	(25.63)
	Provision for Impairment of Financial Assets (net)	(295.61)	99.24
	Operating cash flows before movement in working capital	**3,637.81**	**3,643.84**
	Movements in working capital		
	Adjustment for decrease in operating assets:		
	Inventories	997.04	(61.00)
	Trade Receivables and Other assets	3,478.18	(2,598.16)
	Adjustment for decrease in operating liabilities:		
	Trade Payables and other liabilities	(6,180.57)	(3,099.16)
	Cash generated from/ (used in) operating activities	**1,932.46**	**(2,114.48)**
	Net income tax paid	(480.21)	(30.68)
	Net Cash generated from/ (used in) operating activities (A)	**1,452.25**	**(2,145.16)**
B	**Cash flows from investing activities**		
	Payment for purchase of Property, Plant & Equipment, Capital Work-in-Progress, intangibles, and intangible under development	(1,347.84)	(1,040.07)
	Proceeds from sale of property, plant and equipment and Capital Work-in-Progress	30.18	797.72
	Loans given to subsidiary	(4,764.95)	(3,378.75)
	Loans repaid by subsidiary	4,755.00	150.00
	Interest received on Loans given to subsidiaries	192.26	-
	Loans given to Employees (net)	(5.88)	(47.67)
	Bank deposits placed (net)	21.89	(1.61)
	Interest received	6.61	68.20
	Net Cash generated from/ (used in) investing activities (B)	**(1,112.73)**	**(3,452.18)**
C	**Cash flows from financing activities**		
	Proceeds from non-current borrowings	773.80	-
	Repayments of non-current borrowings	-	(18.29)
	Proceeds of short-term borrowings (net)	(267.17)	3,472.56
	Payment of lease liabilities (Principal)	(307.22)	(279.41)
	Payment of lease liabilities (Interest)	(46.61)	(72.76)
	Professional fees for technical and commercial diligence	-	-
	Finances costs paid	(706.39)	(835.89)
	Net cash generated from/ (used in) financing activities (C)	**(553.59)**	**2,266.21**
	Net (decrease)/increase in cash and cash equivalents (A+B+C)	**(214.07)**	**(3,331.13)**
	Cash and cash equivalents at the beginning of the period	642.33	3,625.41
	Cash and cash equivalents at the end of the period	**428.26**	**294.28**
	Reconciliation of cash and cash equivalents		
	Closing balance of cash and cash equivalents	428.26	294.28
	Cash and cash equivalents at the end of the period	**428.26**	**294.28**

Sahajanand Medical Technologies Limited MUMBAI

DELOITTE HASKINS & SELLS LLP MUMBAI